ReNeuron continues to recruit patients into the extension Phase 2a of its crucial Phase 2a trial of human retinal progenitor cells (hRPC) for retinitis pigmentosa (RP). All nine planned patients should have been treated by the end of 2021 allowing an interim readout by the end of March 2022. This will help ReNeuron to evaluate how to progress the project. The investment case rests largely on a hRPC licensing deal. On the exosome platform, ReNeuron reported the specific delivery of a potent growt ....
10 Dec 2021
Exosomes float into focus in H1 FY21 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exosomes float into focus in H1 FY21 results
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
10 Dec 2021 -
Author:
David Johnson | Robin Davison -
Pages:
7
ReNeuron continues to recruit patients into the extension Phase 2a of its crucial Phase 2a trial of human retinal progenitor cells (hRPC) for retinitis pigmentosa (RP). All nine planned patients should have been treated by the end of 2021 allowing an interim readout by the end of March 2022. This will help ReNeuron to evaluate how to progress the project. The investment case rests largely on a hRPC licensing deal. On the exosome platform, ReNeuron reported the specific delivery of a potent growt ....